382 related articles for article (PubMed ID: 31589320)
1. Modeling Breast Cancer Using CRISPR-Cas9-Mediated Engineering of Human Breast Organoids.
Dekkers JF; Whittle JR; Vaillant F; Chen HR; Dawson C; Liu K; Geurts MH; Herold MJ; Clevers H; Lindeman GJ; Visvader JE
J Natl Cancer Inst; 2020 May; 112(5):540-544. PubMed ID: 31589320
[TBL] [Abstract][Full Text] [Related]
2. Tumor suppressor role of cytoplasmic polyadenylation element binding protein 2 (CPEB2) in human mammary epithelial cells.
Tordjman J; Majumder M; Amiri M; Hasan A; Hess D; Lala PK
BMC Cancer; 2019 Jun; 19(1):561. PubMed ID: 31185986
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9 mediated knockout of rb1 and rbl1 leads to rapid and penetrant retinoblastoma development in Xenopus tropicalis.
Naert T; Colpaert R; Van Nieuwenhuysen T; Dimitrakopoulou D; Leoen J; Haustraete J; Boel A; Steyaert W; Lepez T; Deforce D; Willaert A; Creytens D; Vleminckx K
Sci Rep; 2016 Oct; 6():35264. PubMed ID: 27739525
[TBL] [Abstract][Full Text] [Related]
4. Role of RB1 in human embryonic stem cell-derived retinal organoids.
Zheng C; Schneider JW; Hsieh J
Dev Biol; 2020 Jun; 462(2):197-207. PubMed ID: 32197890
[TBL] [Abstract][Full Text] [Related]
5. CRISPR-mediated direct mutation of cancer genes in the mouse liver.
Xue W; Chen S; Yin H; Tammela T; Papagiannakopoulos T; Joshi NS; Cai W; Yang G; Bronson R; Crowley DG; Zhang F; Anderson DG; Sharp PA; Jacks T
Nature; 2014 Oct; 514(7522):380-4. PubMed ID: 25119044
[TBL] [Abstract][Full Text] [Related]
6. A versatile modular vector system for rapid combinatorial mammalian genetics.
Albers J; Danzer C; Rechsteiner M; Lehmann H; Brandt LP; Hejhal T; Catalano A; Busenhart P; Gonçalves AF; Brandt S; Bode PK; Bode-Lesniewska B; Wild PJ; Frew IJ
J Clin Invest; 2015 Apr; 125(4):1603-19. PubMed ID: 25751063
[TBL] [Abstract][Full Text] [Related]
7. Probing the Tumor Suppressor Function of BAP1 in CRISPR-Engineered Human Liver Organoids.
Artegiani B; van Voorthuijsen L; Lindeboom RGH; Seinstra D; Heo I; Tapia P; López-Iglesias C; Postrach D; Dayton T; Oka R; Hu H; van Boxtel R; van Es JH; Offerhaus J; Peters PJ; van Rheenen J; Vermeulen M; Clevers H
Cell Stem Cell; 2019 Jun; 24(6):927-943.e6. PubMed ID: 31130514
[TBL] [Abstract][Full Text] [Related]
8. [Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].
Sun SJ; Huo JH; Geng ZJ; Sun XY; Fu XB
Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):253-256. PubMed ID: 29690746
[TBL] [Abstract][Full Text] [Related]
9. Establishment of TP53-knockout canine cells using optimized CRIPSR/Cas9 vector system for canine cancer research.
Eun K; Park MG; Jeong YW; Jeong YI; Hyun SH; Hwang WS; Kim SH; Kim H
BMC Biotechnol; 2019 Jan; 19(1):1. PubMed ID: 30606176
[TBL] [Abstract][Full Text] [Related]
10. Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.
Lõhmussaar K; Kopper O; Korving J; Begthel H; Vreuls CPH; van Es JH; Clevers H
Nat Commun; 2020 May; 11(1):2660. PubMed ID: 32461556
[TBL] [Abstract][Full Text] [Related]
11. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
[TBL] [Abstract][Full Text] [Related]
12. Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer.
Liu JC; Granieri L; Shrestha M; Wang DY; Vorobieva I; Rubie EA; Jones R; Ju Y; Pellecchia G; Jiang Z; Palmerini CA; Ben-David Y; Egan SE; Woodgett JR; Bader GD; Datti A; Zacksenhaus E
Cell Rep; 2018 Apr; 23(1):112-126. PubMed ID: 29617654
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas 9 genome editing and its applications in organoids.
Driehuis E; Clevers H
Am J Physiol Gastrointest Liver Physiol; 2017 Mar; 312(3):G257-G265. PubMed ID: 28126704
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9 treatment causes extended TP53-dependent cell cycle arrest in human cells.
Geisinger JM; Stearns T
Nucleic Acids Res; 2020 Sep; 48(16):9067-9081. PubMed ID: 32687165
[TBL] [Abstract][Full Text] [Related]
15. Applications of kidney organoids derived from human pluripotent stem cells.
Kim YK; Nam SA; Yang CW
Korean J Intern Med; 2018 Jul; 33(4):649-659. PubMed ID: 29961307
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Radiation Sensitivity Differences in Mouse Liver Tumor Organoids Using CRISPR/Cas9-Mediated Gene Mutation.
Jeon W; Jung SY; Lee CY; Kim WT; Kim H; Jang KW; Lim H; Lee M; Jeong DH; Kim SD; Kim IA; Choi SH; Son TG; Kim KS
Technol Cancer Res Treat; 2023; 22():15330338231165125. PubMed ID: 36960537
[TBL] [Abstract][Full Text] [Related]
17. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.
Lyu C; Shen J; Wang R; Gu H; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang X; Cheng T; Yang R; Zhang L
Stem Cell Res Ther; 2018 Apr; 9(1):92. PubMed ID: 29625575
[TBL] [Abstract][Full Text] [Related]
18. Engineering human knock-in organoids.
Yang Q; Oost KC; Liberali P
Nat Cell Biol; 2020 Mar; 22(3):261-263. PubMed ID: 32123334
[No Abstract] [Full Text] [Related]
19. CRISPR used to create mouse models.
Cancer Discov; 2014 Nov; 4(11):1248-9. PubMed ID: 25367932
[No Abstract] [Full Text] [Related]
20. Use of CRISPR/Cas Genome Editing Technology for Targeted Mutagenesis in Rice.
Xu R; Wei P; Yang J
Methods Mol Biol; 2017; 1498():33-40. PubMed ID: 27709567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
